The pharmacological treatment and management of obesity (Q30399340)

21 June 2017

1 reference

title

The pharmacological treatment and management of obesity (English)

1 reference

21 June 2017

0 references

1 reference

Syed Sufyan Hussain

1

1 reference

PubMed ID

21293082

21 June 2017

Stephen Robert Bloom

series ordinal

2

1 reference

PubMed ID

21293082

21 June 2017

language of work or name

English

0 references

publication date

1 January 2011

1 reference

21 June 2017

Postgraduate Medicine

1 reference

21 June 2017

123

1 reference

21 June 2017

1

1 reference

21 June 2017

34-44

1 reference

Prevalence and trends in obesity among US adults, 1999-2008

21 June 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Medical Consequences of Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Bowels control brain: gut hormones and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

The fundamental drivers of the obesity epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Lifestyle modification for the management of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Caloric restriction delays disease onset and mortality in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Popular diets: a scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Dietary adherence and weight loss success among overweight women: results from the A TO Z weight loss study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Sitting time and mortality from all causes, cardiovascular disease, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Effects of the amount of exercise on body weight, body composition, and measures of central obesity: STRRIDE--a randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Effect of exercise on 24-month weight loss maintenance in overweight women

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Drug treatment of the overweight patient

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Comparison of continuous and intermittent anorectic therapy in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Valvular heart disease associated with fenfluramine-phentermine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Zonisamide for weight loss in obese adults: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Meta-analysis: surgical treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Hospital complication rates with bariatric surgery in Michigan

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

The cost, quality of life impact, and cost-utility of bariatric surgery in a managed care population

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Multicenter, placebo-controlled trial of lorcaserin for weight management

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Inhibition of food intake in obese subjects by peptide YY3-36

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Serum immunoreactive-leptin concentrations in normal-weight and obese humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Effects of recombinant leptin therapy in a child with congenital leptin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Can gut hormones control appetite and prevent obesity?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Pancreatic polypeptide reduces appetite and food intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Critical role of arcuate Y4 receptors and the melanocortin system in pancreatic polypeptide-induced reduction in food intake in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Low-fat diets and energy balance: how does the evidence stand in 2002?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Carbohydrate for weight and metabolic control: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

Adherence to Mediterranean diet and health status: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

The evolution of very-low-calorie diets: an update and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.01.2243

21 January 2018

Identifiers

DOI

10.3810/PGM.2011.01.2243

1 reference

21 June 2017

1 reference

PubMed ID

21293082